Life Sciences Financing Survey - First Half, 2013

In This Issue:

- Summary

- Analysis of Industry Data

- Detailed Fenwick & West Results: Valuation

- Detailed Fenwick & West Results: Financing Terms

- About This Survey

- Excerpt from Overview of Results:

While the first half of 2013 saw a surge in initial public offerings (IPOs) by venture-backed biopharma companies, the overall financing environment for privately held life science companies remains slow.

The average valuation increase for life science companies receiving venture capital financing during the first half of 2013 was roughly even with 2012 results, and the percentage of “up round” financings declined slightly. Fundraising by life science venture capitalists continued to decline as well.

Please see full survey below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Biotechnology, Financing, Life Sciences, Pharmaceutical

Published In: General Business Updates, Finance & Banking Updates, Health Updates, Science, Computers & Technology Updates, Securities Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Fenwick & West LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »